Abstract
Selecting the most appropriate animal species for toxicity testing increases the likelihood of detecting potential effects in humans. Regulatory guidelines provide a framework for the development of appropriate and meaningful nonclinical programs for both chemically synthesized pharmaceuticals and biotherapeutic products. In the case of small molecules, a key factor in species selection is determining the metabolic profiles (similarities and differences) between candidate species and human. For biotherapeutics, species selection is based on pharmacological relevance (expressed target receptor or epitope and appropriate functional engagement) that evokes a similar pharmacological response as that expected in humans. The rat is the predominant rodent species of choice based on size and extensive historical database. The rationale for selecting the appropriate nonrodent species among commonly used toxicology species including dog, minipig, rabbit, and nonhuman primate (NHP) is more challenging and should be a science-based and data driven decision to meet regulatory expectations and not a default to a preferred species. In particular, the use of the NHP should be scientifically and ethically justified in terms of benefits and pharmacological relevance, as well as consideration to the 3R principles. This chapter aims to provide an introduction to the selection of relevant animal species for toxicology studies for small molecules and biotherapeutics. A firm understanding of the regulatory requirements for pharmaceuticals for human use will ensure that the most sensitive and regulatory-compliant animal species are utilized to maximize the chances of gaining regulatory approval for clinical testing or market authorization in the shortest time frame.
References and Further Reading
Actemra (tocilizumab): Genentech, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125276s092lbl.pdf. Accessed Aug 2022
Aguilera B, Perez Gomez J, DeGrazia D (2021) Should biomedical research with great apes be restricted? A systematic review of reasons. BMC Med Ethics 22:15
Ali S, Kolter K (2019) Kolliphor® HS 15 – an enabler for parenteral and oral formulations. Am Pharm Rev, 25 Feb 2019. https://www.americanpharmaceuticalreview.com/Featured-Articles/358749-Kolliphor-HS-15-An-Enabler-for-Parenteral-and-Oral-Formulations/. Accessed July 2022
Allio T (2018) The FDA animal rule and its role in protecting human safety. Expert Opin Drug Saf 17(10):971–973
Animals (Scientific Procedures) Act 1986 Amendment Regulations (2012) https://www.legislation.gov.uk/ukdsi/2012/9780111530313. Accessed July 2022
Arcalyst (rilonacept): Regeneron Pharmaceuticals, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf. Accessed Aug 2022
Arora T, Mehta AK, Joshi V (2011) Substitute of animals in drug research: an approach towards fulfillment of 4R’s. Indian J Pharm Sci 73(1):1–6
Audia A, Bannish G, Bunting R et al (2022) Flow cytometry and receptor occupancy in immune-oncology. Expert Opin Bio Ther 22(1):87–94
Avila AM, Bebenek I, Bonzo JA et al (2020) An FDA/CDER perspective on nonclinical testing strategies: classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol 114:104662
Baldrick P (2008) Safety evaluation to support first-in-man investigations II: toxicology studies. Regul Toxicol Pharmacol 51(2):237–243
Baldrick P, Reeve L (2007) Carcinogenicity evaluation: comparison of tumor data from dual control groups in the CD-1 mouse. Toxicol Pathol 35(4):562–575
Baumann B, Schirmer J, Rauscher S et al (2015) Melanin pigmentation in rat eyes: in vivo imaging by polarization-sensitive optical coherence tomography and comparison to histology. Invest Ophthalmol Vis Sci 56(12):7462–7472
Beermann F, Orlow S, Lamoreux M (2004) The Tyr (albino) locus of the laboratory mouse. Mamm Genome 15:749–758
Bogdanffy MS, Lesniak J, Mangipudy R et al (2020) Tg.rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals: industry survey of current practices. Int J Toxicol 39(3):198–206
Bradley A, Mukaratirwa S, Petersen-Jones M (2012) Incidences and range of spontaneous findings in the lymphoid and haemopoietic system of control Charles River CD-1 mice (Crl: CD-1(ICR) BR) used in chronic toxicity studies. Toxicol Pathol 40(2):375–381
Brennan FR, Morton LD, Spindeldreher S et al (2010) Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2(3):233–255
Brennan FR, Cavagnaro J, McKeever K (2018) Safety testing of monoclonal antibodies in non-human primates: case studies highlighting their impact on human risk assessment. mAbs 10(1):1–17
Buckley LA, Chapman K, Burns-Naas LA et al (2011) Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. Int J Toxicol 30(5):583–590
Bugelski PJ, Martin PL (2012) Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol 166:823–846
Bussiere JL, Martin P, Horner M et al (2009) Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 28(3):230–253
Cauvin AJ, Peters C, Brennan F (2015) Advantages and limitations of commonly used nonhuman primate species in research and development of biopharmaceuticals. In: Blumel J, Korte S, Schnenck E, Weinbauer G (eds) The nonhuman primate in nonclinical drug development and safety assessment, 1st edn. Academic/Elsevier, London, pp 379–395
Chamanza R, Marxfeld HA, Blanco AI et al (2010) Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. Toxicol Pathol 38(4):642–657
Chamanza R, Naylor SW, Gregori M et al (2022) The influence of geographical origin, age, sex, and animal husbandry on the spontaneous histopathology of laboratory cynomolgus macaques (Macaca fascicularis): a contemporary global and multisite review of historical control data. Toxicol Pathol 50(5):607–627
Chapman K, Burnett J, Corvaro M et al (2014a) Reducing pre-clinical blood volumes for toxicokinetics: toxicologists, pathologists and bioanalysts unite. Bioanalysis 6(22):2965–2968
Chapman K, Chivers S, Gliddon D (2014b) Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies. Drug Discov Today 19(5):528–532
Charng J, Nguyen C, Bui B et al (2011) Age-related retinal function changes in albino and pigmented rats. Invest Ophthalmol Vis Sci 52:8891–8899
Cimzia (certolizumab pegol): UCB, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf. Accessed Aug 2022
Coleman K, Novak MA (2017) Environmental enrichment in the 21st century. ILAR J 58:295–307
Colleton C, Brewster D, Chester A et al (2016) The use of minipigs for preclinical safety assessment by the pharmaceutical industry: results of an IQ druSafe minipig survey. Toxicol Pathol 44(3):458–466
Corvi R, Madia F, Guyton KZ et al (2017) Moving forward in carcinogenicity assessment: report of an EURL ECVAM/ESTIV workshop. Toxicol In Vitro 45(3):278–286
Dalgaard L (2015) Comparison of minipig, dog, monkey and human drug metabolism and disposition. J Pharmacol Toxicol Methods 74:80–92
Directive 2010/63/EU. Annex VIII, Section 1. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF. Accessed 16 July 2022
Dogterom P, Zbinden G, Reznik GK (1992) Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview. Crit Rev Toxicol 22:203–241
Dorso L, Chanut F, Howroyd P et al (2008) Variability in weight and histological appearance of the prostate of beagle dogs used in toxicology studies. Toxicol Pathol 36(7):917–925
du Sert NP, Holmes AM, Wallis R et al (2012) Predicting the emetic liability of novel chemical entities: a comparative study. Br J Pharmacol 165(6):1848–1867
Ellenbroek B, Youn J (2016) Rodent models in neuroscience research: is it a rat race? Dis Model Mech 9(10):1079–1087
EMA (European Medicines Agency) (2017) EMEA/CHMP/SWP/28367/07 Rev. 1. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products
EMA (European Medicines Agency) (2018) Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use. https://www.ema.europa.eu/en/polysorbates
Emmerich CH, Gamboa LM, Hofmann MCJ et al (2021) Improving target assessment in biomedical research: the GOT-IT recommendations. Nat Rev Drug Discov 20:64–81
Esteves PJ, Abrantes J, Baldauf HM et al (2018) The wide utility of rabbits as models of human diseases. Exp Mol Med 50:1–10
Ettlin RA, Kuroda J, Plassmann S et al (2010) Successful drug development despite adverse preclinical findings part 2: examples. J Toxicol Pathol 23(4):213–234
Evans DT, Silvestri G (2013) Nonhuman primate models in AIDS research. Curr Opin HIV AIDS 8(4):255–261
Fan J, Chen Y, Yan H et al (2018) Principles and applications of rabbit models for atherosclerosis research. J Atheroscler Thromb 25(3):213–220
Faqi AS (2012) A critical evaluation of developmental and reproductive toxicology in nonhuman primates. Syst Biol Reprod Med 58(1):23–32
Gad SC (1990) Symposium V: models for experimentation in toxicology – refinements, improvements, and alternatives presented at the tenth annual meeting of the American college of toxicology, October 30–November 1, 1989. J Am Coll Toxicol 9(3):289–289
Ganderup NC, Harvey W, Mortensen JT et al (2012) The minipig as nonrodent species in toxicology-where are we now? Int J Toxicol 31:507–528
Gardner MB, Luciw PA (2008) Macaque models of human infectious disease. ILAR J 49(2):220–255
Grimaldi C, Finco D, Fort MM et al (2016) Cytokine release: a workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine 85:101–108
Haese NN, Roberts VHJ, Chen A et al (2021) Nonhuman primate models of Zika virus infection and disease during pregnancy. Viruses 13(10):2088
Han HJ, Powers SJ, Gabrielson KL (2022) The common marmoset-biomedical research animal model applications and common spontaneous diseases. Toxicol Pathol 50(5):628–637
Hannibal DL, Bliss-Moreau E, Vandeleest J et al (2017) Laboratory rhesus macaque social housing and social changes: implications for research. Am J Primatol 79(1):1–14
Harvey W (2012) Regulatory acceptance of the minipig in non-pharmaceutical industry and research. In: McAnulty P, Dayan A, Ganderup N-C, Hastings K (eds) The minipig in biomedical research. CRC Press Taylor & Francis Group, Boca Raton
Hayakawa K, Mimura Y, Tachibana S et al (2013) Study for collecting background data on Wistar Hannover [Crl:WI(Han)] rats in general toxicity studies–comparative data to Sprague Dawley rats. J Toxicol Sci 38:855–873
Hayes TJ, Roberts GKS, Halliwell WH (1989) An idiopathic febrile necrotizing arteritis syndrome in the dog: beagle pain syndrome. Toxicol Pathol 17(1_part_2):129–137
Heining P, Ruysschaert T (2016) The use of minipig in drug discovery and development: pros and cons of minipig selection and strategies to use as a preferred nonrodent species. Toxicol Pathol 44(3):467–473
Henze LJ, Koehl NJ, O’Shea JP et al (2019) The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review. J Pharm Pharmacol 71:581–602
Horner S, Ryan D, Robinson S et al (2013) Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas. Regul Toxicol Pharmacol 65:334–343
ICH M3(R2) (2009) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. In: International Conference for Harmonisation (ICH). Topic M3(R2)
ICH S1B(R1) (2022) Testing for carcinogenicity of pharmaceuticals. In: International Conference for Harmonisation (ICH). Topic S1B(R1)
ICH S3A (1994) Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies. In: International Conference for Harmonisation (ICH). Topic S3A
ICH S5(R3) (2020) Detection of reproductive and developmental toxicity for human pharmaceuticals. In: International Conference for Harmonisation (ICH). Topic S5(R3)
ICH S6(R1) (2011) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. In: International Conference for Harmonisation (ICH). Topic S6(R1)
ICH S9 (2009) Nonclinical evaluation for anticancer pharmaceuticals. In: International Conference on Harmonisation (ICH). Topic S9
Ilaris (canakinumab): Novartis Pharmaceuticals Corporation. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/BLA125319_858687lbl.pdf. Assessed Aug 2022
Jena GB, Chavan S (2017) Implementation of Good Laboratory Practices (GLP) in basic scientific research: translating the concept beyond regulatory compliance. Regul Toxicol Pharmacol 89:20–25
Johnson AL, Keesler RI, Lewis AD et al (2022) Common and not-so-common pathologic findings of the gastrointestinal tract of rhesus and cynomolgus macaques. Toxicol Pathol 50(5):638–659
Kirk RGW (2018) Recovering the principles of humane experimental technique: the 3Rs and the human essence of animal research. Sci Technol Hum Values 43(4):622–648
Kissner T, Blaich G, Baumann A et al (2021) Challenges of non-clinical safety testing for biologics: a report of the 9th BioSafe European Annual General Membership Meeting. mAbs 13:1938796
Klingemann H (2021) Immunotherapy for dogs: still running behind humans. Front Immunol 12:665784
Köhn F (2012) History and development of miniature, micro- and minipigs. In: McAnulty P, Dayan A, Ganderup N-C, Hastings K (eds) The minipig in biomedical research. CRC Press Taylor & Francis Group, Boca Raton
Kohn DF, Clifford CB (2002) Biology and diseases of rats. Lab Anim Med:121–165
Kreger M, Farris M (2003) International transportation of nonhuman primates: US fish and wildlife service perspective. In: International perspectives: the future of nonhuman primate resources. NRC. The National Academies Press, Washington, DC
Kuramoto T, Nakanishi S, Ochiai M et al (2012) Origins of albino and hooded rats: implications from molecular genetic analysis across modern laboratory rat strains. PLoS One 7(8):e43059
Lee H (2022) Obesity-associated cancers: evidence from studies in mouse models. Cell 11:1472
Liang M, Schwickart M, Schneider AK et al (2016) Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom 90(2):117–127
Lu S, Zhao Y, Yu W et al (2020) Comparison of nonhuman primates identified the suitable model for COVID-19. Sig Transduct Target Ther 5(1):157
Lynch CM, Hart BW, Grewal IS (2009) Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. MAbs 1(1):2–11
Makurvet FD (2021) Biologics vs. small molecules: drug costs and patient access. Med Drug Discov 9:100075
Mapara M, Thomas BS, Bhat KM (2012) Rabbit as an animal model for experimental research. Dent Res J (Isfahan) 9(1):111–118
Meyer O, Svendsen O (2003) Animal models in pharmacology and toxicology, Chapter 2. In: Hau J, Van Hoosier GL Jr (eds) Handbook of laboratory animal science/volume II animal models, 2nd edn. CRC Press LLC, Boca Raton, p 11
Morton DM (1998) Importance of species selection in drug toxicity testing. Toxicol Lett 102–103:545–550
Namdari R, Jones K, Chuang SS (2021) Species selection for nonclinical safety assessment of drug candidates: examples of current industry practice. Regul Toxicol Pharmacol 126:105029
Nunoya T, Shibuya K, Saitoh T et al (2007) Use of miniature pig for biomedical research, with reference to toxicologic studies. J Toxicol Pathol 20:125–132
Nürnberg A, Pierre H (2017) An introduction to little-known aspects of nonclinical regulatory writing. Eur Med Writ Assoc 26(4):9–19
OECD (1997) Principles on good laboratory practice. https://www.oecd.org/chemicalsafety/testing/good-laboratory-practiceglp.htm. Accessed 16 Aug 2022
Oglesbee BL, Lord B (2020) Gastrointestinal diseases of rabbits. In: Quesenberry KE, Orcutt CJ, Mans C, Carpenter JW (eds) Ferrets, rabbits, and rodents. Clinical medicine and surgery, 4th edn. Elsevier, St. Louis, pp 174–187
Okamura T, Suzuki S, Ogawa T et al (2011) Background data for general toxicology parameters in RccHan:WIST Rats at 8, 10, 19 and 32 weeks of age. J Toxicol Pathol 24(4):195–205
Olson H, Betton G, Robinson D et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67
Padrell M, Llorente M, Amici F (2021) Invasive research on non-human primates—time to turn the page. Animals 11(10):2999
Parish ST, Aschner M, Casey W et al (2020) An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regul Toxicol Pharmacol 112:104592
Prior H, Sewell F, Stewart J (2017) Overview of 3Rs opportunities in drug discovery and development using non-human primates. Drug Discov Today Dis Model 23:11–16
Prior H, Monticello T, Boulifard V et al (2019) Integration of consortia recommendations for justification of animal use within current and future drug development paradigms. Int J Toxicol 38(4):319–325
Prior H, Baldrick P, Beken S et al (2020a) Opportunities for use of one species for longer-term toxicology testing during drug development: a cross-industry evaluation. Regul Toxicol Pharmacol 113:104624
Prior H, Haworth R, Labram B (2020b) Justification for species selection for pharmaceutical toxicity studies. Toxicol Res 9(6):758–770
Prueksaritanont T, Tang C (2012) ADME of biologics-what have we learned from small molecules? AAPS J 14(3):410–419
Remicade (infliximab): Janssen Biotech, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf. Accessed Aug 2022
Rosso MC, Badino P, Ferrero G (2016) Biologic data of cynomolgus monkeys maintained under laboratory conditions. PLoS One 11(6):e0157003
Rozkot M, Václavková E, Bělková J (2015) Minipigs as laboratory animals – review. Res Pig Breed 9:10–14
Sakai C, Iwano S, Yamazaki Y et al (2014) Species differences in the pharmacokinetic parameters of cytochrome P450 probe substrates between experimental animals, such as mice, rats, dogs, monkeys, and microminipigs, and humans. J Drug Metab Toxicol 5(6):1000173
Sanger GJ, Andrews PLR (2018) A history of drug discovery for treatment of nausea and vomiting and the implications for future research. Front Pharmacol 9:913
Sasseville VG, Diters RW (2008) Impact of infections and normal flora in nonhuman primates on drug development. ILAR J 49(2):179–190
Sato J, Doi T, Kanno T, Wako Y et al (2012) Histopathology of incidental findings in cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. J Toxicol Pathol 25(1):63–101
Schaefer K, Rensing S, Hillen H et al (2016) Is science the only driver in species selection? An internal study to evaluate compound requirements in the minipig compared to the dog in preclinical studies. Toxicol Pathol 44(3):474–479
Sécher T, Bodier-Montagutelli E, Guillon A et al (2020) Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals. Adv Drug Deliv Rev 167:148–169
Sewell F, Chapman K, Couch J et al (2017) Challenges and opportunities for the future of monoclonal antibody development: improving safety assessment and reducing animal use. MAbs 9(5):742–755
Shen J, Swift B, Mamelok R et al (2019) Design and conduct considerations for first-in-human trials. Clin Transl Sci 12(1):6–19
Smith D, Trennery P (2002) Non-rodent selection in pharmaceutical toxicology. A ‘points to consider’ document, developed by the ABPI in conjunction with the UK Home Office. https://www.abpi.org.uk/media/1644/non-rodent-selection.pdf. Accessed 16 July 2022
Smith D, Trennery P, Farningham D et al (2001) The selection of marmoset monkeys (Callithrix jacchus) in pharmaceutical toxicology. Lab Anim 35(2):117–130
Son W-C, Gopinath C (2004) Early occurrence of spontaneous tumors in CD-1 Mice and Sprague – Dawley rats. Toxicol Pathol 32(4):371–374
Son YW, Choi HN, Che JH et al (2020) Advances in selecting appropriate non-rodent species for regulatory toxicology research: policy, ethical, and experimental considerations. Regul Toxicol Pharmacol 116:104757
Spilker ME, Singh P, Vicini P (2016) Mathematical modeling of receptor occupancy data: a valuable technology for biotherapeutic drug development. Cytometry B Clin Cytom 90(2):230–236
Stricker-Krongrad A, Shoemake CR, Liu J et al (2017) The importance of minipigs in dermal safety assessment: an overview. Cutan Ocul Toxicol 36:105–113
Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028
Svendsen O (2006) The minipig in toxicology. Exp Toxicol Pathol 57:335–339
Swindle MM, Makin A, Herron AJ et al (2012) Swine as models in biomedical research and toxicology testing. Vet Pathol 49(2):344–356
t’Hart BA, Abbott DH, Nakamura K et al (2012) The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov Today 17(21–22):1160–1165
Tamaki C, Nagayama T, Hashiba M et al (2013) Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. J Toxicol Sci 38:581–598
Tang H, Mayersohn M (2018) Porcine prediction of pharmacokinetics in people. Drug Metab Dispos 46(11):1712–1724
Trepanier LA, Ray K, Winand NJ et al (1997) Cytosolic arylamine n-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 54(1):73–80
US Congress FDA Modernisation Act 2.0 (2022) https://www.congress.gov/bill/117th-congress/senate-bill/5002. Accessed 17 Mar 2023
US Food and Drug Administration (1987) 21CFR58 code of Federal Regulations Title 21. Good Laboratory Practice for Nonclinical Laboratory Studies. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58. Accessed 16 Aug 2022
US Food and Drug Administration (2004) Cetuximab pharmacology review. https://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125084_ERBITUX_PHARMR_P1.PDF. https://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125084_ERBITUX_PHARMR_P2.PDF. https://www.accessdata.fda.gov/drugsatfda_docs/bla/2004/125084_ERBITUX_PHARMR_P3.PDF. Accessed 27 Aug 2022
US Food and Drug Administration (2005) Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. https://www.fda.gov/media/72309/download. Accessed 19 June 2022
US Food and Drug Administration (2015) Guidance for industry: product development under the Animal Rule. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf. Accessed 16 Aug 2022
US Food and Drug Administration (2020) Guidance for industry: safety testing of drug metabolites-Center for Evaluation and Research (CDER). https://www.fda.gov/media/72279/download. Accessed Aug 2022
US Food and Drug Administration (2022) Guidance for Industry: nonclinical considerations for mitigating nonhuman primate supply constraints arising from the COVID-19 pandemic. https://www.fda.gov/media/155950/download. Accessed 16 Aug 2022
Vargason AM, Anselmo AC, Mitragotri S (2021) The evolution of commercial drug delivery technologies. Nat Biomed Eng 5:951–967
Vargesson N (2015) Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 105(2):140–156
Vugmeyster Y, Xu X, Theil FP et al (2012) Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 3(4):73–92
Wang X, An Z, Luo W et al (2018) Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein Cell 9:74–85
Warne RK, Moloney GK, Chaber A-L (2023) Is biomedical research demand driving a monkey business? One Health 16:100520
Weber K, Razinger T, Hardisty JF et al (2011) Differences in rat models used in routine toxicity studies. Int J Toxicol 30(2):162–173
Webster J, Bollen P, Grimm H et al (2010) Ethical implications of using the minipig in regulatory toxicology studies. J Pharmacol Toxicol Methods 62(3):160–166
Whiteside GT, Kennedy JD (2010) Consideration of pharmacokinetic pharmacodynamic relationships in the discovery of new pain drugs, Chapter 16. In: Kruger L, Light AR (eds) Translational pain research: from mouse to man. CRC Press/Taylor & Francis, Boca Raton. https://www.ncbi.nlm.nih.gov/books/NBK57267/
Wolfreys A, Kilgour J, Allen AD et al (2021) Review of the technical, toxicological, and PKPD considerations for conducting inhalation toxicity studies on biologic pharmaceuticals-the outcome of a cross-industry working group survey. Toxicol Pathol 49(2):261–285
Zuch de Zafra CL, Sasseville VG, Matsumoto S et al (2017) Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics. Regul Toxicol Pharmacol 86:221–230
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Harvey, W.D. (2023). Species Selection for Pharmaceutical Toxicity Studies. In: Hock, F.J., Gralinski, M.R., Pugsley, M.K. (eds) Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Springer, Cham. https://doi.org/10.1007/978-3-030-73317-9_133-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-73317-9_133-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-73317-9
Online ISBN: 978-3-030-73317-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences